Vertex Pharmaceuticals Inc

VRTX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
H?fLOCK|@V>dLOCK|r<CPwGP

Vertex: Positive Phase 3 Data for Povetacicept Brings $4.9 Billion Alpine Deal Closer to Payoff

Vertex Pharmaceuticals reported positive phase 3 data for povetacicept in IgA nephropathy, a chronic kidney disease that can lead to renal failure, showing a 49.8% reduction in proteinuria compared with placebo and meeting all primary and secondary endpoints. Shares rose 8% on March 10.

Sponsor Center